Sun Pharmaceutical Industries Limited — Cyborg Score 7/10
Solid
Generic and specialty pharmaceuticals
Strategic Profile
Sun Pharma's diversified business mix—including India formulations (33% of revenue), emerging markets, US generics, and specialty medicines—enables balanced growth, with the company maintaining 8.4% market share as India's leading pharmaceutical player. The company is expanding its innovative product portfolio with US launches (Unloxcyt) and India introductions (Ilumya) to drive differentiated therapy offerings.
Cyborg Score Rationale
FY26 showed strong consolidated revenue growth of 11.9% and EBITDA expansion of 16.1%, demonstrating operational momentum. India formulations grew 16.2% in Q3, accounting for 32% of sales with market-leading share of 8.4%. However, US formulation sales declined 0.9%, creating near-term headwinds in a key market.
Top Insights
India formulation business growing 14% and contributing 33% of consolidated revenue, with Sun Pharma holding the #1 position and 8.4% market share in India's ₹2,407 billion pharma market as of March 2026.
Emerging markets sales grew 13.6% to US$1,265 million in FY26, offsetting flat US generics (down 0.9%).
New specialty medicine launches—UNLOXCYT in the US and ILUMYA in India—received encouraging early feedback during Q3 FY26.
EBITDA margin expansion of 16.1% demonstrates operational leverage, though net profit growth of 5% suggests earnings constrained relative to revenue growth.
Named Competitors
Cipla — Large-cap Indian pharma competitor in generics, branded, and specialty medicines
Lupin — Indian multinational pharma with generics and specialty focus
Dr. Reddy's — Indian pharma multinational competing in generics and APIs
Aurobindo — Indian pharma competitor in injectables, generics, and APIs
Recent Developments
(March 2026) FY26 revenue grew 11.9% to ₹582 billion; EBITDA up 16.1%; net profit up 5% to ₹115 billion.
(January 2026) Q3 FY26 revenue grew 15.1% to ₹154.7 billion; net profit up 16% YoY on strong branded business and new product launches.
(January 2026) Launched UNLOXCYT in US and ILUMYA in India; India formulation sales grew 16.2% in Q3 FY26.
Open the full interactive Sun Pharmaceutical Industries Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.